251 related articles for article (PubMed ID: 36154436)
1. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
2. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
3. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
4. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
5. Polio endgame: the global switch from tOPV to bOPV.
Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
[TBL] [Abstract][Full Text] [Related]
6. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
7. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
[TBL] [Abstract][Full Text] [Related]
8. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
9. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
10. Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
Menning L; Garg G; Pokharel D; Thrush E; Farrell M; Kodio FK; Veira CL; Wanyoike S; Malik S; Patel M; Rosenbauer O
J Infect Dis; 2017 Jul; 216(suppl_1):S24-S32. PubMed ID: 28838189
[TBL] [Abstract][Full Text] [Related]
11. Polio endgame: the global introduction of inactivated polio vaccine.
Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
[TBL] [Abstract][Full Text] [Related]
12. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z
Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421
[TBL] [Abstract][Full Text] [Related]
13. Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
Patel M; Cochi S
J Infect Dis; 2017 Jul; 216(suppl_1):S1-S8. PubMed ID: 28838196
[TBL] [Abstract][Full Text] [Related]
14. The polio endgame: rationale behind the change in immunisation.
Garon J; Patel M
Arch Dis Child; 2017 Apr; 102(4):362-365. PubMed ID: 28096107
[TBL] [Abstract][Full Text] [Related]
15. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Duintjer Tebbens RJ; Thompson KM
Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
[TBL] [Abstract][Full Text] [Related]
16. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
17. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
18. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
19. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
Badizadegan K; Kalkowska DA; Thompson KM
Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
[TBL] [Abstract][Full Text] [Related]
20. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]